Reader View AI Reader View Novo Nordisk's Wegovy Pill Is Capturing 80% of New Oral Obesity Prescriptions. Is NVO Stock a Buy? www.nasdaq.com · November 21, 2026 · 22:35 Paywall detected This article has a paywall The publisher blocks direct access to this article. Generate with AI Open link